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Abstract
Study Design—Cross-sectional study.
Objectives—Determine clinical factors associated with plasma C-reactive protein (CRP) in 
persons with chronic spinal cord injury (SCI).
Setting—Veterans Affairs Medical Center in Boston, MA.
Methods—Participants provided a blood sample, completed a respiratory health questionnaire, 
and underwent dual x-ray absorptiometry (DXA) to assess total and regional body fat. Linear 
regression models were used to assess cross-sectional associations with plasma CRP.
Results—In multivariable models, factors associated with a higher CRP included a greater BMI, 
urinary catheter use, a respiratory illness in the past week, and non-white race. Mean CRP also 
increased with decreasing mobility (motorized wheel chair >hand propelled wheel chair > walk 
with an assistive device > walk independently). Results were similar when adjusting for % 
android, gynoid, trunk, or total fat mass in place of BMI. Level and completeness of SCI was not 
associated with CRP in multivariable models.
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Conclusions—Clinical characteristics common in chronic SCI are associated with plasma CRP. 
These factors are more important than level and completeness of SCI and some are potentially 
modifiable.
Keywords
C-reactive protein; body fat; spinal cord injury
Introduction
Chronic spinal cord injury (SCI) is characterized by clinical factors that promote systemic 
inflammation including reduced mobility,1-5 accumulation of central fat,6-8 and recurrent 
infections.9-10 The linkage between systemic inflammation as assessed by C-reactive protein 
(CRP) and the development of atherosclerosis and coronary heart disease is well established.
11
 As individuals with SCI age, they are at increased risk for developing cardiovascular 
disease,12 which has become a major cause of mortality in the SCI population.13-18
Although elevated CRP levels have previously been described in chronic SCI,19-22 to date, 
there has been a limited description of clinical factors that contribute. Slowly healing 
pressure ulcers in 34 men with SCI,9 urinary tract infections in 37 men,10 tetraplegia 
compared to paraplegia in 69 men and women,23 and greater fat mass and body mass index 
(BMI) in 77 men and women have been associated with elevated CRP levels.24 In a previous 
report in 63 individuals, we found that mobility mode, a greater BMI, heart disease, and a 
pressure ulcer reported in the past year, were each associated with higher circulating CRP.25 
A limitation of these previous reports, however, is a reduced ability to assess multiple 
covariates due to small sample sizes. The objective of this report is to assess the robustness 
of our previous findings in a new chronic SCI cohort with more than five times as many 
participants, as well as to assess the impact of additional factors, including fat mass assessed 
by dual x-ray absorptiometry (DXA) on levels of CRP.
Methods
Subjects
Between 8/2009 and 4/2015 we recruited 360 individuals into a study of respiratory health 
among individuals with chronic SCI. Participants were recruited from patients receiving care 
at VA Boston, from the greater Boston area through advertisement, and by direct mail to 
persons who had received care at Spaulding Rehabilitation Hospital, Boston University 
Medical Center, were members of the National Spinal Cord Injury Association, or were 
subscribers to New Mobility Magazine. Individuals were eligible if they were 22 years of 
age or older, were 1 or more years post-injury, had no other neuromuscular disease, did not 
have a tracheostomy, and were able to breathe without chronic ventilatory support. 
Participants were eligible regardless of etiology of SCI and testing was scheduled when 
subjects were free of acute illness. The Institutional Review Board at VA Boston Healthcare 
System approved the protocol and informed consent was obtained. We certify that all 
applicable institutional and governmental regulations concerning the ethical use of human 
volunteers were followed during the course of this research.
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Neurological exam, stature, and weight
SCI level and severity was assessed by exam and medical record review.26 Motor incomplete 
SCI included AIS C (most key muscles below the neurological level grade < 3/5) or AIS D 
(most muscles below the neurological level grade ≥ 3/5). For analysis, participants were 
further grouped into cervical motor complete (AIS A or B) and cervical AIS C, high thoracic 
(T1-T6) complete (AIS A or B) and AIS C, others with T7 or below motor complete (AIS A 
or B) or AIS C, and all others (AIS D’s). Height was obtained by measuring the body length 
from top of the head to the heel of the subject in a supine position. Supine length was 
measured in 307 (91%) and obtained by self-report in 31 (9%) when contractures precluded 
accurate measurement. If required, wheelchairs were weighed with and without the 
participant, and wheelchair weight subtracted. In 5 persons, self-report of weight was used. 
BMI (kg/m2) was calculated from height and weight.
Dual x-ray absorptiometry (DXA) for % body fat
A 5th generation GE Healthcare iDXA scanner was used to assess % total body, % trunk, % 
android, and % gynoid fat using GE Lunar software analyzed by a certified clinical 
densitometrist (AAL). Daily quality assurance was performed utilizing a phantom. The trunk 
region was defined by cuts passing through the shoulders and extended inferiorly as close to 
the body as possible through the femoral necks. The lower boundary of the android region 
was a horizontal cut at the level of the iliac crests and the upper boundary extended upwards 
to 20% of the distance between the pelvis and shoulders. For the gynoid region, the upper 
boundary was the iliac crests and the lower boundary included the pelvis and extended 
downward 1.5 times the height of the android region.
Health Questionnaire
A questionnaire based on American Thoracic Society Division of Lung Diseases ATS 
DLD-7827 was used to obtain a history of cigarette smoking, comorbid medical diseases, 
and statin use. Hypertension, diabetes, and asthma were defined based on report of a 
diagnosis by a doctor, and chronic obstructive pulmonary disease (COPD) was defined as 
either doctor-diagnosed emphysema or chronic bronchitis. Heart disease was defined as 
treatment for “heart trouble” reported in the 10 years prior to study entry. Participants were 
asked to report if a chest illness kept them off work, indoors at home, or in bed in the 
previous one and three years, if they had had a respiratory illness in the past week, if they 
currently had a urinary tract infection (UTI) or a skin ulcer, or if they had experienced either 
in the past one and three years, how they usually passed urine, and if they received regular 
dental care. Usual mobility mode (more than 50% of the time) was ascertained in four 
categories: motorized wheelchair use, hand-propelled wheelchair use, walk with aid such as 
crutch or cane, or walk without assistance.
Biochemical Analyses
Plasma samples were drawn into an EDTA tube and immediately delivered to a core blood 
research laboratory. The samples were centrifuged for 15 min at 2600 rpm (1459 x g) at 4°C 
and stored at -80°C until batch analysis. High sensitivity CRP concentrations using an 
immunoturbidimetric assay were determined at the Clinical & Epidemiologic Research 
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Laboratory, Department of Laboratory Medicine at Children’s Hospital in Boston. This 
assay has a sensitivity of 0.03 mg/L. The day-to-day variability of the assay at 
concentrations of 0.91, 3.07, and 13.38 mg/L are 2.81, 1.61, and 1.1%, respectively.
Statistical Analysis
We excluded persons without a detectable SCI level (n=3), history of stroke (n=2), 
incomplete data collection (n=6), inability to obtain blood (n=6), incomplete data on body 
composition (n=4), or without CRP results (n=1), leaving a sample size of 338 participants. 
There were 26 subjects who participated in our previous study (2004-2005)25 who were 
retested. Natural log-transformation of CRP was used to meet modeling assumptions. 
General linear models (PROC GLM, SAS version 9.4) were used to assess determinants of 
natural log CRP. A Tukey adjustment was used for multiple comparisons. Trends across %-
fat and BMI quartiles were assessed using the median values and trends for mobility and 
SCI categories assessed by assigning ordinal numbers. Variables significant in univariable 
models at the 0.10 level or less were included in multivariate models. We a priori assessed 
characteristics associated with infection (i.e., ulcer history) and considered effects of 
comorbid diseases as potential confounders.
Results
Participant Characteristics
Participant characteristics are presented in Table 1 overall and by primary mobility mode. 
The mean ± standard deviation age and injury duration were 54.1±14.4 years and 17.3±13.3 
years, respectively (Table 1). The majority of participants were male (82%) and white 
(86%). When screened by questionnaire at the time of testing, a mild cold or other 
respiratory illness was reported by 26 persons (7.7%) in the past week. A history of skin 
ulcers, urinary tract infections, and catheter use were more common among motorized and 
hand-propelled wheelchair users. There were 83 people (25%) with CRP levels <1 mg/L 
(defined as low cardiovascular risk),11 105 (31%) with CRP levels of 1-3mg/L, and 150 
(44%) with CRP levels of >3 mg/L). There were 54 (16%) with very high CRP levels 
(>10mg/L). The distribution of natural log CRP was normally distributed (Shapiro-Wilks 
test W=0.996, p=0.640) and there was no evidence of outliers.
Univariable associations
In univariable models, age, sex, injury duration, smoking status and pack-years of smoking, 
sex, statin use, dental care, and comorbidities were not associated with CRP (Table 2). Both 
mobility mode and level and completeness of SCI were statistically significantly associated 
with CRP, with the highest CRP levels observed among motorized wheelchair users and 
among cervical motor complete and AIS C SCI with a significant linear trend across 
mobility and SCI level and completeness categories (Table 2). Persons who reported a 
current skin ulcer or a UTI or reported either in the past one and three years had higher CRP 
levels compared to persons without these conditions. Persons who used a condom catheter, a 
chronic indwelling catheter, or used periodic catheterization had CRP values that were not 
statistically significantly different from one another (p=0.551-0.999), but each was 
statistically significantly different from participants who did not use a catheter. Therefore, 
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catheter use was considered as a dichotomous variable. Catheter use was strongly 
assocciated with report of a current UTI as 21 out of the 25 persons with a current UTI used 
a catheter. Persons who reported a respiratory illness (4.10; 95%CI: 2.28, 5.01mg/L) in the 
past week had greater CRP values compared to persons without an illness (2.54; 95%CI: 
2.14, 2.97 mg/L, p=0.096). Participants who were self-identified as being white had lower 
CRP values compared to non-white participants (p=0.038). Each measure of adiposity was 
also statistically significantly positively associated with CRP, with a significant trend across 
quartiles (Table 3).
Multivariable associations
Due to the high level of collinearity between the DXA-derived measures of adiposity 
(Pearson r=0.705-0.979, p<0.0001) and a significant correlation between these measures 
with BMI (r=0.393-0.689, p<0.0001), we created five multivariable models including each 
adiposity measure separately with other predictors (Table 4). Each adiposity measure 
(including BMI) were statistically significantly associated with CRP levels in multivariate 
models (p<0.001). There was a significant positive linear trend across adiposity measure 
quartiles (not shown), so the continuous measures were used in the final models. Urinary 
catheter use also remained statistically significantly associated with CRP (p=0.002-0.013), 
with a better model fit than either current UTI or UTI in the previous year. Participants with 
a respiratory illness in the week before testing (usually a mild cold) had significantly greater 
CRP levels (p=0.005-0.015), as did those who identified as non-white (p=0.001-0.041). In 
each model (Table 4), participants who reported a current ulcer had a higher CRP compared 
to persons without an ulcer that was not statistically significant (p=0.096-0.173). 
Associations with an ulcer reported in the past year (p=0.254-0.450) were weaker and not 
significant.
In four multivariable models (Table 4), there was a significant linear trend across mobility 
categories with CRP (p<0.001-0.018), and a suggestive relationship in an additional model 
(p=0.069). When included in these models SCI level and completeness was not a statistically 
significant predictor of CRP (p=0.554-0.974).
Effect of chronic disease
In order to account for effects of comorbid diseases on CRP as potential confounders, we 
individually added heart disease, diabetes, hypertension, COPD, asthma, and any obstructive 
lung disease (asthma or COPD) into the final multivariable models. The effects of measures 
of adiposity, urinary catheter, respiratory illness in the past week, current skin ulcer, race, 
and mobility mode did not meaningfully change (data not shown). Heart disease was 
significantly associated with a greater CRP (p=0.021-0.039) in all models as was 
hypertension in the model that included gynoid fat (p=0.015). Hypertension in other models 
(p=0.100-0.157), diabetes (p=0.198-0.770), COPD (p=0.786-0.976), asthma 
(p=0.163-0.372), and any obstructive lung disease (asthma or COPD) (p=0.305-0.440) were 
not significantly associated with CRP.
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Discussion
In this cross-sectional study in a cohort of individuals with chronic SCI, we found that 
measures of adiposity (BMI, % total body fat, % trunk fat, % android fat, and % gynoid fat), 
mobility mode, catheter use, race, and respiratory illness in the past week were all 
independently associated with circulating levels of CRP. There was a strong linear 
association found between SCI level and CRP in univariable models (p<.0001) that was not 
evident after adjustment for mobility mode. We previously reported similar results in a 
smaller study (n=63) in our earlier chronic SCI cohort, indicating that these findings are 
reproducible in the SCI population.25 The effects of clinical factors identified in 
multivariable models were not affected after adjustment for comorbidities that included heart 
disease, hypertension, diabetes, COPD, and asthma. Although heart disease history was 
significantly associated with a higher CRP value in multivariate models, it did not confound 
the relationship between the clinical factors included in the multivariable models and CRP.
Pressure ulcers and UTI’s have been previously associated with an elevated CRP levels.9-10 
The participants in this cohort were tested when they were feeling well and were able to sit 
upright for study-related procedures. This likely explains why relatively few persons 
reported a current skin ulcer (11.2%), and its weak association with CRP in the multivariate 
models. Considerably more persons (25.2%) reported a skin ulcer in the past year. Similarly, 
few persons in our cohort reported a current UTI (7.4%), but many reported having a UTI in 
the past year (40.2%). Both chronic, intermittent, and condom catheter use are known 
correlates of chronic bacteriuria and pyuria28 which is most likely responsible for the higher 
CRP values associated with catheter use.
We directly assessed percent fat in the android, gynoid, and trunk regions as well as total 
body fat by DXA scan. In SCI, due to a decrease in lean mass and increase in increase in fat 
mass and in central (truncal) fat,6-7,29 BMI may not accurately assess adiposity.30 However, 
we found similar effects of BMI and other measures of adiposity on CRP levels in 
multivariate models, most likely attributable to the high degree of correlation between the fat 
measures.
Our findings support the hypothesis that physiologic changes that occur following SCI 
attributable to decreased mobility, bladder dysfunction, and skin ulcers contribute to CRP 
and systemic inflammation, and therefore, potentially future risk of cardiovascular disease. 
Many studies in persons without SCI have found higher levels of CRP to be an associated 
with lower levels of physical activity.1-3,31 Evidence that chronic or recurrent infection may 
be associated with cardiovascular disease comes from positive associations between 
periodontal disease and carotid intima-media thickness,32 and the timing of a myocardial 
infarction and a preceding systemic respiratory tract33 or urinary tract infection34 in persons 
without chronic SCI.
A considerable stength of this study is the use of a comprehensive standardized approach 
allowing the consideration of multiple factors potentially associated with CRP in a large 
chronic SCI cohort. Limitations includes reliance on self report of current ulcer, UTI and of 
chronic medical conditions. However, we have previously validated the use of self-report of 
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chronic medical conditions in this population.14 Misclassification would make it more 
difficult to detect the true associations with CRP.
Our study findings support the importance of studying modifiable factors in chronic SCI that 
can impact on health. A longitudinal study is needed to assess relationship between factors 
identified, chronic elevations in CRP, and subsquent effects on cardiovacular health. 
Addressing modifiable factors related to obesity, reduced physical actvity, and recurrent 
infection could potentially help in lowering the risk of cardiovascular disease among those 
with chronic SCI.
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TABLE 2
Univariable associations with ln CRP (mg/L; N=338)
Clinical factors, continuous covariates e(β) e(95% CI) p-value
Age (yrs) 1.00 0.99, 1.01 0.960
Injury Duration (yrs) 1.00 0.99, 1.01 0.689
Pack Years 1.00 1.00, 1.01 0.165
Clinical factors, categorical covariates e(ln mean CRP) e (95% CI) p
Sex 0.374
 Female 2.27 1.59, 3.25
 Male 2.71 2.30, 3.20
Race 0.038
 White 2.47 2.10, 2.90
 Non-white 3.92 2.61, 5.89
SCI Classification p-trend<0.001
 Motor complete cervical & AIS C 4.02 2.97, 5.43
 Motor complete high thoracic* & AIS C 3.57 2.40, 5.31
 Other motor complete & AIS C 3.00 2.16, 4.16
 All AIS D 1.77 1.41, 2.21
Mobility mode p-trend<0.001
 Motorized wheelchair 5.53 3.98, 7.68
 Hand propelled wheelchair 2.79 2.25, 3.45
 Walk with aid 2.22 1.56, 3.14
 Walk without assistance 1.31 0.95, 1.81
Skin Ulcers
 Now 2.40 2.05, 2.81 <0.001
  None now 5.38 3.45, 8.37
 In the past year 4.03 2.99, 5.41 0.001
  None in the past year 2.28 1.92, 2.71
 In the past 3 years 3.85 2.96, 5.01 0.001
  None in the past 3 years 2.28 1.84, 2.63
Uses urinary catheter
 Yes 3.67 3.02, 4.45 <0.001**
  Periodic catheterization 3.36 2.60, 4.34
  Chronic catheter 4.55 3.14, 6.59
  Condom catheter 3.48 2.14, 5.67
 No 1.70 3.02, 4.45
Urinary Tract Infections (UTIs)
 Now 4.94 2.85, 8.56 0.020
  None now 2.50 2.14, 2.92
 In the past year 3.61 2.86, 4.56 <0.001
  None in the past year 2.12 1.75, 2.57
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Clinical factors, continuous covariates e(β) e(95% CI) p-value
 In the past 3 years 2.93 2.41, 3.56 0.094
  None in the past 3 years 2.26 1.78, 2.85
Current statin use 0.166
 Yes 2.25 1.73, 2.94
 No 2.83 2.36, 3.39
Regular dental care 0.894
 Yes 2.61 2.09, 3.39
 No 2.66 2.15, 3.17
Chest illness in the past year 0.807
 Yes 2.50 1.62, 3.85
 No 2.65 2.25, 3.11
Chest illness in the past 3 years (n=337) 0.184
 Yes 3.14 2.31, 4.26
 No 2.47 2.08, 2.94
Respiratory illness in the past week (n=336) 0.096
 Yes 4.10 2.28, 5.01
 No 2.54 2.14, 2.97
Heart disease 0.325
 Yes 3.24 2.08, 5.05
 No 2.56 2.18, 3.00
COPD 0.351
 Yes 2.12 1.32, 3.41
 No 2.69 2.30, 3.16
Ashma 0.958
 Yes 2.60 1.72, 3.93
 No 2.63 2.24, 3.10
Doctor diagnosed COPD or asthma 0.417
 Yes 2.33 1.68, 3.24
 No 2.71 2.29, 3.22
Diabetes 0.518
 Yes 2.96 2.00, 4.38
 No 2.58 2.19, 3.03
Hypertension 0.378
 Yes 2.87 2.24, 3.69
 No 2.50 2.07, 3.02
Smoking Status 0.751
 Current 2.95 2.06, 4.24
 Former 2.63 2.08, 3.33
 Never 2.50 1.97, 3.17
*high thoracic=T1-T6
**Catheter/no catheter
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